Cetuximab Boosts Survival in Patients With Liver MetsCetuximab Boosts Survival in Patients With Liver Mets
Cetuximab combined with chemotherapy improved the resectability of liver metastases and survival in patients with KRAS wild-type colorectal cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ADC: The Next Big Opportunity For Oncology Drugs
The commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 27, 2013 Category: Pharmaceuticals Source Type: news
Adding Cetuximab Harmful in Esophageal Cancer Treatment
SAN FRANCISCO (IMNG) - A phase II/III clinical trial of adding cetuximab to chemoradiotherapy for localized esophageal cancer was stopped early when interim results showed greater toxicity, less completion... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 5, 2013 Category: Cancer & Oncology Source Type: news
Erbitux Add-On Falls Short in Esophageal Ca (CME/CE)
SAN FRANCISCO (MedPage Today) -- The addition of cetuximab (Erbitux) to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 27, 2013 Category: Gastroenterology Source Type: news
BMJ analysis: Optional copayments on anti-cancer drugs
Source: BMJ
Area: News
In this BMJ analysis, the authors note that "new cancer drugs are often expensive and offer low cost effectiveness, yet funders find it hard to resist the pressure to provide them to dying patients." They argue that because these drugs have only marginal efficacy it is reasonable to ask patients to contribute to their excess costs through optional copayments.
Their article covers the following topics:
. Example of bevacizumab and cetuximab
. The regulatory game
. General argument for copayments
. Copayments and expensive cancer drugs
. Effec...
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news
Daiichi Sankyo-ArQule Phase II study of tivantinib fails to meet primary endpoint
Daiichi Sankyo and ArQule have announced that a Phase II study of tivantinib (ARQ 197) used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer (CRC) did not meet the primary endpoint of progression-… (Source: Drug Development Technology)
Source: Drug Development Technology - January 14, 2013 Category: Pharmaceuticals Source Type: news
NCCN Adds Survivorship Section to Colon and Rectal Cancer Guidelines
NCCN announces new modifications to the NCCN Guidelines for Colon and Rectal Cancers. Important additions include a new survivorship section, new indications for cetuximab as it relates to KRAS gene testing, and recommendations on how to re-evaluate patients initially presenting with unresectable disease. Colorectal cancer remains the third most frequently diagnosed cancer in men and women in the United States.
February 18, 2009
FORT WASHINGTON, PA - The National Comprehensive Cancer Netwo... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 18, 2009 Category: Cancer & Oncology Source Type: news
Important Updates to the NCCN Drugs & Biologics Compendium Non-Small Cell Lung Cancer
FORT WASHINGTON, Pa., September 10, 2008 — The National Comprehensive Cancer Network, (NCCN), announces important updates to the NCCN DrugsandBiologics Compendium Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows:
Cetuximab (Erbitux, Bristol-Myers Squibb/ImC lone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 10, 2008 Category: Cancer & Oncology Source Type: news
Important Updates to the NCCN Drugs & Biologics Compendium Non-Small Cell Lung Cancer
FORT WASHINGTON, Pa., September 10, 2008 — The National Comprehensive Cancer Network, (NCCN), announces important updates to the NCCN DrugsandBiologics Compendium Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows:
Cetuximab (Erbitux, Bristol-Myers Squibb/ImClone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 10, 2008 Category: Cancer & Oncology Source Type: news
